Radionuclide-based theranostics - a promising strategy for lung cancer

Area of Science:

• Oncology
• Nuclear Medicine
• Radiopharmaceutical Chemistry

Background:

• Lung cancer remains a leading cause of cancer mortality globally.
• Tumor heterogeneity necessitates personalized treatment approaches.
• Theranostics, combining imaging and therapy with radionuclides, offers a promising strategy for systemic cancer management.

Purpose of the Study:

• To provide a comprehensive review of recent literature on personalized lung cancer management.
• To focus on the application of various ligands and radionuclide-based tumor-targeting agents.
• To highlight advances in precision medicine for lung cancer.

Main Methods:

• Summarizing current radiotracers and radioligand therapeutic agents for lung cancer diagnosis and treatment.
• Discussing clinical applications and limitations of target-dependent radiotracers.
• Reviewing therapeutic radionuclides and their role in personalized medicine.

Main Results:

• Radionuclide-based theranostics demonstrate significant potential for tailored cancer care.
• Recent advances include novel radioligands and radionuclide agents for lung cancer.
• Careful consideration of target, ligand, and radionuclide is crucial for effective lung cancer theranostics.

Conclusions:

• Radionuclide-based theranostics hold great promise for personalized lung cancer management.
• This review aims to enhance understanding of the latest radionuclide therapies for lung cancer.
• The study promotes the wider application of radioligand theranostics in precision oncology.